The American Journal of Managed Care

Lower Risk of Recurrent Clostridioides difficile Infections Shown Over Past Decade

A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...
Medical Xpress

High-dose VE303 prevents recurrent clostridioides difficile infection

For adults with laboratory-confirmed Clostridioides difficile infection (CDI) at high risk for recurrence, high-dose VE303, a defined bacterial consortium of eight strains of commensal Clostridia, ...
The American Journal of Managed Care

Microbiota-Based Therapeutic May Reduce Clostridioides Difficile Infection Recurrence

New data suggest a microbiota-based therapy can reduce C diff recurrence in patients where donor microbiota and patient microbiota successfully converge. A new report suggests microbiota-based ...
Medical Xpress

Vancomycin trial shows no significant reduction in recurrent C. diff infections

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides difficile (C. diff) among adults given low-dose oral vancomycin during ...
MedPage Today

Oral Microbiome Therapy for Recurrent C. Diff Mostly Holds Up at 6 Months

WASHINGTON -- Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.
Infection control

Recurrent C Difficile: Evaluating Patients’ Physical, Mental, Social Outlooks

The Clostridioides difficile Health-related Quality-of-Life Questionnaire responses demonstrated patients handled the situation better with specific investigational treatments. According to some data, ...
PR Newswire

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) ...
Monthly Prescribing Reference

Ridinilazole Reduces C difficile Infection Recurrence More Effectively Than Vancomycin

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...
Business Wire

Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from its Phase 3 ECOSPOR III study evaluating SER-109, an ...
News Medical

The burden of Clostridioides difficile infections in the United States

In a recent review published in BMC Infectious Diseases, researchers reviewed existing data on Clostridioides difficile infections (CDI) among United States residents. CDIs have caused considerable ...
Yahoo Finance

Elaris Advances C. difficile Vaccine Beyond Toxin-Only Approaches with Matrivax Asset Acquisition

VIENNA, May 5, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced that it has entered into an ...